{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/framework-assessing-viability-externally-controlled-arm-single-arm-trial#webpage",
"url": "https://www.fortrea.com/insights/framework-assessing-viability-externally-controlled-arm-single-arm-trial",
"name": "A framework for assessing the viability of an externally controlled arm for a single-arm trial",
"description": "This Fortrea white paper explores pediatric clinical trial approaches for metabolic dysfunction-associated steatotic liver disease across pediatric hepatology research settings. The content focuses on metabolic dysfunction-associated steatotic liver disease, pediatric clinical trials, study design strategies, patient recruitment challenges, pediatric study endpoints, and liver disease research approaches affecting pediatric trial development. The white paper highlights factors related to pediatric patient enrollment, disease progression assessment, endpoint consistency, and evolving clinical understanding within pediatric MASLD studies. Fortrea discusses clinical and research perspectives designed to support pediatric trial planning, strengthen study design approaches, and improve research strategies associated with pediatric hepatology programs. By integrating pediatric study planning with endpoint and liver disease research approaches, the white paper provides insights into pediatric clinical trial strategies for metabolic dysfunction-associated steatotic liver disease and broader pediatric hepatology research programs."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "A framework for assessing the viability of an externally controlled arm for a single-arm trial",
"item": "https://www.fortrea.com/insights/framework-assessing-viability-externally-controlled-arm-single-arm-trial"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/conducting-pediatric-trials-metabolic-dysfunction-associated-steatotic-liver-disease-masld#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/conducting-pediatric-trials-metabolic-dysfunction-associated-steatotic-liver-disease-masld#webpage"
},
"headline": "A framework for assessing the viability of an externally controlled arm for a single-arm trial",
"description": "This Fortrea white paper explores pediatric clinical trial approaches for metabolic dysfunction-associated steatotic liver disease across pediatric hepatology research settings. The content focuses on metabolic dysfunction-associated steatotic liver disease, pediatric clinical trials, study design strategies, patient recruitment challenges, pediatric study endpoints, and liver disease research approaches affecting pediatric trial development. The white paper highlights factors related to pediatric patient enrollment, disease progression assessment, endpoint consistency, and evolving clinical understanding within pediatric MASLD studies. Fortrea discusses clinical and research perspectives designed to support pediatric trial planning, strengthen study design approaches, and improve research strategies associated with pediatric hepatology programs. By integrating pediatric study planning with endpoint and liver disease research approaches, the white paper provides insights into pediatric clinical trial strategies for metabolic dysfunction-associated steatotic liver disease and broader pediatric hepatology research programs.",
"genre": "White Paper",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-07/framework-externally-controlled-arm-single-arm-trial.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-07-30",
"dateModified": "2025-07-30",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-07/framework-externally-controlled-arm-single-arm-trial.pdf",
"encodingFormat": "application/pdf"
}
}
]
}